← Leaderboards
Mingju Cao
Kinetiq, Inc.
$864,461
Attributed
$864,461
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $602.8K · FY2017–24$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$864,461 · 3
By mechanism
R43$864,461 · 3
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Quality Of Life”
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,912,072
- Martha Hering · Westat, Inc.$57,098,843
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Abraham Aizer Brody · New York University School Of Medicine$40,849,810
- Steven A. Ackerman · University Of Wisconsin-Madison$38,898,438
- Greg Yothers · University Of Chicago$35,003,821
Research focus
Quality Of LifeHeartDoseSmall Business Innovation Research GrantEnzyme Replacement TherapyMorbidity - Disease RateOrganAffectKidneyComplexEnzymesBiodistributionMortalityFabry DiseaseLysosomal Storage DiseasesNerve FibersDrug Or Chemical Tissue DistributionIntravenousIntravenous Infusion ProceduresHospitalsAlpha-GalactosidaseDrug KineticsHourFormulation
Grant awards (4)
Evaluating a Novel Enzymatic Modality for the Treatment of Fanconi Anemia$306,870
R43 · FY2024 · HL · contact PI
Preclinical Efficacy of Subcutaneous Enzyme Therapy for Lysosomal Fabry Disease$295,923
R43 · FY2024 · TR · contact PI
Subcutaneous Replacement Enzymes for Fabry Disease$50,000
R43 · FY2018 · TR · contact PI
Subcutaneous Replacement Enzymes for Fabry Disease$211,668
R43 · FY2017 · TR · contact PI